# US 2016/0251418 A1 · Anti-transthyretin antibodies

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2016/0251418 A1
- Document ID: US20160251418A1
- Status: Published application
- Kind: A1
- Application number: 15/009,662
- Filed: 2016-01-28
- Published: 2016-09-01
- Earliest claimed: 2015-01-28
- Applicants: Prothena Biosciences Limited; University Health Network
- Inventors: Yue Liu; Tarlochan S. Nijjar; Avijit Chakrabartty; Jeffrey N. Higaki
- Web page: https://patentgrep.com/patent/US20160251418A1

## CPC

- C07K 16/18: against material from animals or humans
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/24: Antidepressants
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61K 2039/505: {comprising antibodies}
- C07K 2317/24: containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C07K 2317/34: Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
- C07K 2317/41: Glycosylation, sialylation, or fucosylation
- C07K 2317/56: variable (Fv) region, i.e. VH and/or VL
- C07K 2317/565: Complementarity determining region [CDR]
- C07K 2317/567: Framework region [FR]
- C07K 2317/76: Antagonist effect on antigen, e.g. neutralization or inhibition of binding
- C07K 2317/92: Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention provides antibodies that specifically bind transthyretin (TTR). The antibodies can be used for treating or effecting prophylaxis of diseases or disorders associated with TTR accumulation or accumulation of TTR deposits (e.g., TTR amyloidosis). The antibodies can also be used for diagnosing TTR amyloidosis and inhibiting or reducing aggregation of TTR, among other applications.

## Claims

### Claim 1

An antibody that binds to transthyretin and comprises three heavy chain CDRs and three light chain CDRs substantially from antibody 14G8.

### Claim 2 (depends on 1)

The antibody of claim 1 comprising three Kabat heavy chain CDRs and three Kabat light chain CDRs of the antibody 14G8, except that position L26 can be N or S.

### Claim 3 (depends on 1)

The antibody of claim 1 comprising three Kabat heavy chain CDRs and three Kabat light chain CDRs of the antibody 14G8.

### Claim 4 (depends on 1)

The antibody of claim 1 wherein CDR-H1 is a composite Kabat-Chothia CDR of the antibody 14G8.

### Claim 5

An antibody that binds to transthyretin and comprises three heavy chain CDRs and three light chain CDRs substantially from antibody 9D5.

### Claim at position 6

6-8. (canceled)

### Claim 9 (depends on 2)

The antibody of claim 2, wherein
the three heavy chain CDRs and the three light chain CDRs of 14G8 are SEQ ID NOS: 67-69 and 77-79, respectively, except that position L26 can be N or S.

### Claim 10 (depends on 1)

The antibody of claim 1 that is a monoclonal antibody.

### Claim 11 (depends on 1)

The antibody of claim 1 that is a chimeric, humanized, veneered, or human antibody.

### Claim 12 (depends on 1)

The antibody of claim 1 that has human IgG1 isotype.

### Claim 13 (depends on 1)

The antibody of claim 1 that has human IgG2 or IgG4 isotype.

### Claim at position 12

14-34. (canceled)

### Claim 35 (depends on 9)

The humanized antibody of claim 9 comprising a humanized mature heavy chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOS: 64-66 and a humanized mature light chain variable region having an amino acid sequence at least 90% identical to any one of SEQ ID NOS: 74-76, except that position H82a can be N or S, position H83 can be R or K, position H84 can be A or S, position H89 can be V or M, and position L18 can be S or P.

### Claim 36 (depends on 35)

The humanized antibody of claim 35, wherein at least one of the following positions is occupied by the amino acid as specified: position H1 is occupied by E, position H47 is occupied by L, and position L36 is occupied by F.

### Claim 37 (depends on 36)

The humanized antibody of claim 36, wherein positions H1 and H47 are occupied by E and L, respectively.

### Claim 38 (depends on 36)

The humanized antibody of claim 36, wherein position L36 is occupied by F.

### Claim 39 (depends on 35)

The humanized antibody of claim 35, wherein at least one of the following positions is occupied by the amino acid as specified: position H3 is occupied by K or Q, position H105 is occupied by T or Q, position L8 is occupied by A or P, position L9 is occupied by P or L, position L19 is occupied by V or A, position L26 is occupied by S or N, position L60 is occupied by S or D, and position L70 is occupied by A or D.

### Claim at position 18

40-42. (canceled)

### Claim 43 (depends on 35)

The humanized antibody of claim 35, comprising a mature heavy chain variable region having an amino acid sequence at least 95% identical to any one of SEQ ID NOS: 64-66 and a mature light chain variable region having an amino acid sequence at least 95% identical to any one of SEQ ID NOS: 74-76, except that position H82a can be N or S, position H83 can be R or K, position H84 can be A or S, position H89 can be V or M, and position L18 can be S or P.

### Claim 44 (depends on 43)

The humanized antibody of claim 43, comprising a mature heavy chain variable region having an amino acid sequence at least 98% identical to any one of SEQ ID NOS: 64-66 and a mature light chain variable region having an amino acid sequence at least 98% identical to any one of SEQ ID NOS: 74-76, except that position H82a can be N or S, position H83 can be R or K, position H84 can be A or S, position H89 can be V or M, and position L18 can be S or P.

### Claim 45 (depends on 44)

The humanized antibody of claim 44, wherein the mature heavy chain variable region has an amino acid sequence of any one of SEQ ID NOS: 64-66, and the mature light chain variable region has an amino acid sequence of any one of SEQ ID NOS: 74-76.

### Claim 46 (depends on 45)

The humanized antibody of claim 45, wherein the mature heavy chain variable region has an amino acid sequence of SEQ ID NO: 65 and the mature light chain variable region has an amino acid sequence of SEQ ID NO: 76.

### Claim 47 (depends on 1)

The antibody of claim 1 that is an intact antibody.

### Claim 48 (depends on 1)

The antibody of claim 1 that is a binding fragment.

### Claim 49 (depends on 48)

The antibody of claim 48, wherein the binding fragment is a single-chain antibody, Fab, or Fab′2 fragment.

### Claim 50 (depends on 9)

The humanized antibody of claim 9, wherein the mature light chain variable region is fused to a light chain constant region and the mature heavy chain variable region is fused to a heavy chain constant region.

### Claim 51 (depends on 50)

The humanized antibody of claim 50, wherein the heavy chain constant region is a mutant form of a natural human heavy chain constant region which has reduced binding to a Fcγ receptor relative to the natural human heavy chain constant region.

### Claim 52 (depends on 50)

The humanized antibody of claim 50, wherein the heavy chain constant region is of IgG1 isotype.

### Claim 53 (depends on 50)

The humanized antibody of claim 50, wherein the mature heavy chain variable region is fused to a heavy chain constant region having the sequence of SEQ ID NO: 103 and/or the mature light chain variable region is fused to a light chain constant region having the sequence of SEQ ID NO: 104 or 105.

### Claim 54 (depends on 9)

The humanized antibody of claim 9, provided
any differences in CDRs of the mature heavy chain variable region and mature light chain variable region from SEQ ID NOS: 61 and 70, respectively, reside in positions H60-H65, except that position L26 can be N or S.

### Claim 55 (depends on 1)

A pharmaceutical composition comprising the antibody of claim 1 and a pharmaceutically acceptable carrier.

### Claim 56 (depends on 1)

A nucleic acid encoding the heavy chain and/or light chain of an antibody as described in claim 1.

### Claim 57

(canceled)

### Claim 58 (depends on 56)

A recombinant expression vector comprising a nucleic acid of claim 56.

### Claim 59 (depends on 58)

A host cell transformed with the recombinant expression vector of claim 58.

### Claim 60

A method of humanizing an antibody, the method comprising:
(a) selecting one or more acceptor antibodies;
(b) identifying the amino acid residues of the mouse antibody to be retained;
(c) synthesizing a nucleic acid encoding a humanized heavy chain comprising CDRs of the mouse antibody heavy chain and a nucleic acid encoding a humanized light chain comprising CDRs of the mouse antibody light chain; and
(d) expressing the nucleic acids in a host cell to produce a humanized antibody;
wherein the mouse antibody is 14G8, wherein 14G8 is characterized by a mature heavy chain variable region of SEQ ID NO: 61 and a mature light chain variable region of SEQ ID NO: 70.

### Claim 61

A method of producing a humanized, chimeric, or veneered antibody, the method comprising:
(a) culturing cells transformed with nucleic acids encoding the heavy and light chains of the antibody, so that the cells secrete the antibody; and
(b) purifying the antibody from cell culture media;
wherein the antibody is a humanized, chimeric, or veneered form of 14G8.

### Claim 62

A method of producing a cell line producing a humanized, chimeric, or veneered antibody, the method comprising:
(a) introducing a vector encoding heavy and light chains of an antibody and a selectable marker into cells;
(b) propagating the cells under conditions to select for cells having increased copy number of the vector;
(c) isolating single cells from the selected cells; and
(d) banking cells cloned from a single cell selected based on yield of antibody;
wherein the antibody is a humanized, chimeric, or veneered form of 14G8.

### Claim 63 (depends on 62)

The method of claim 62, further comprising propagating the cells under selective conditions and screening for cell lines naturally expressing and secreting at least 100 mg/L/106 cells/24 h.

### Claim 64 (depends on 1)

A method of inhibiting or reducing aggregation of transthyretin in a subject having or at risk of developing a transthyretin-mediated amyloidosis, comprising administering to the subject an effective regime of the antibody of claim 1, thereby inhibiting or reducing aggregation of transthyretin in the subject.

### Claim 65 (depends on 1)

A method of inhibiting or reducing transthyretin fibril formation in a subject having or at risk of developing a transthyretin-mediated amyloidosis, comprising administering to the subject an effective regime of the antibody of claim 1, thereby inhibiting or reducing transthyretin accumulation in the subject.

### Claim 66 (depends on 1)

A method of reducing transthyretin deposits in a subject having or at risk of developing a transthyretin-mediated amyloidosis, comprising administering to the subject an effective regime of the antibody of claim 1, thereby reducing transthyretin deposits in the subject.

### Claim 67 (depends on 1)

A method of clearing aggregated transthyretin in a subject having or at risk of developing a transthyretin-mediated amyloidosis, comprising administering to the subject an effective regime of the antibody of claim 1, thereby clearing aggregated transthyretin from the subject relative to a subject having or at risk of developing a transthyretin-mediated amyloidosis who has not received the antibody.

### Claim 68 (depends on 1)

A method of stabilizing a non-toxic conformation of transthyretin in a subject having or at risk of developing a transthyretin-mediated amyloidosis, comprising administering to the subject an effective regime of the antibody of claim 1, thereby stabilizing a non-toxic conformation of transthyretin in the subject.

### Claim 69 (depends on 1)

A method of treating or effecting prophylaxis of a transthyretin-mediated amyloidosis in a subject, comprising administering to the subject an effective regime of the antibody of claim 1.

### Claim 70 (depends on 1)

A method of delaying the onset of a transthyretin-mediated amyloidosis in a subject, comprising administering to the subject an effective regime of the antibody of claim 1.

### Claim 71 (depends on 1)

A method of diagnosing a transthyretin-mediated amyloidosis in a subject, comprising contacting a biological sample from the subject with an effective amount of the antibody of claim 1.

### Claim at position 48

72-80. (canceled)

### Claim 81 (depends on 1)

A method of detecting the presence or absence of transthyretin deposits in a subject, comprising contacting a biological sample from the subject suspected of comprising the amyloid accumulation with an effective amount of the antibody of claim 1.

### Claim at position 50

82-88. (canceled)

### Claim 89 (depends on 39)

The humanized antibody of claim 39, wherein positions H3, H105, L8, L9, L19, L26, L60 and L70 are occupied by Q, Q, P, L, A, S, S and D, respectively.

### Claim 90 (depends on 43)

The humanized antibody of claim 43, wherein positions H82a, H83, H84, H89 and L18 are occupied by S, K, S, M and P, respectively.
